Craig Slattery
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Craig Slattery has a total of 211 co-authors. Here are the top co-authors by number of shared publications:
- Tara McMorrow
School of Biomolecular and Biomedical Science, Conway Institute, University College Dublin, Dublin, Ireland
28 shared publications Michael P. Ryan
UCD Centre for Toxicology, School of Biomolecular and Biomedical Science, Conway Institute, University College Dublin, Belfield, Dublin 4, Ireland
16 shared publications- Michael P. Ryan
Renal Disease Research Group, School of Biomolecular and Biomedical Science, UCD Conway Institute, University College Dublin, Dublin 4, Ireland
7 shared publications - Paul Jennings
Department of Chemistry and Pharmaceutical Sciences, Vrije Universiteit Amsterdam, Amsterdam Institute of Molecular and Life Sciences (AIMMS), De Boelelaan 1108, 1081 HZ, Amsterdam, The Netherlands.
6 shared publications Robert Radford
Molecular and Cell Biology Laboratory, The Salk Institute for Biological Studies, La Jolla, California, United States of America
6 shared publications- Hilary Cassidy
School of Biomolecular and Biomedical Science, Conway Institute, University College Dublin, Belfield, Dublin, Ireland
5 shared publications
Latest Publications
- Open Access
- 13 November 2026
- Published by Elsevier in Environmental Toxicology and Pharmacology
Assessing occupational exposure to imidacloprid among animal shelter workers using human biomonitoring
- 13 November 2026
- Published by Elsevier in Environmental Toxicology and Pharmacology
Open AccessAssessing occupational exposure to imidacloprid among animal shelter workers using human biomonitoring
- Open Access
- 1 June 2026
- Published by Elsevier in Environment International
- Vol. 213, 110346
A human biomonitoring study evaluating exposure to imidacloprid among pet owners following the use of ectoparasite treatments
- 1 June 2026
- Published by Elsevier in Environment International
- Vol. 213, 110346
Open AccessA human biomonitoring study evaluating exposure to imidacloprid among pet owners following the use of ectoparasite treatments
- Open Access
- 6 April 2026
- Published by Elsevier in Current Opinion in Endocrine and Metabolic Research
- Vol. 43
Advances in experimental models for endocrine-disrupting chemical research across key biological outcomes
- 6 April 2026
- Published by Elsevier in Current Opinion in Endocrine and Metabolic Research
- Vol. 43
Open AccessAdvances in experimental models for endocrine-disrupting chemical research across key biological outcomes
- Open Access
- 7 June 2025
- Published by Elsevier in International Journal of Hygiene and Environmental Health
- Vol. 268, 114610
Characterising neonicotinoid insecticide exposures among the Irish population using human biomonitoring
- 7 June 2025
- Published by Elsevier in International Journal of Hygiene and Environmental Health
- Vol. 268, 114610
Open AccessCharacterising neonicotinoid insecticide exposures among the Irish population using human biomonitoring
- Open Access
Effects of Curcumin Analogues DMC and EF24 in Combination with the Cytokine TRAIL against Kidney Cancer
The natural compound curcumin has been shown to have therapeutic potential against a wide range of diseases such as cancer. Curcumin reduces cell viability of renal cell carcinoma (RCC) cells when combined with TNF-related apoptosis-inducing ligand (TRAIL), a cytokine that specifically targets cancer cells, by helping overcome TRAIL resistance. However, the therapeutic effects of curcumin are limited by its low bioavailability. Similar compounds to curcumin with higher bioavailability, such as demethoxycurcumin (DMC) and 3,5-bis(2-fluorobenzylidene)-4-piperidone (EF24), can potentially have similar anticancer effects and show a similar synergy with TRAIL, thus reducing RCC viability. This study aims to show the effects of DMC and EF24 in combination with TRAIL at reducing ACHN cell viability and ACHN cell migration. It also shows the changes in death receptor 4 (DR4) expression after treatment with these compounds individually and in combination with TRAIL, which can play a role in their mechanism of action.
Open AccessEffects of Curcumin Analogues DMC and EF24 in Combination with the Cytokine TRAIL against Kidney Cancer
The natural compound curcumin has been shown to have therapeutic potential against a wide range of diseases such as cancer. Curcumin reduces cell viability of renal cell carcinoma (RCC) cells when combined with TNF-related apoptosis-inducing ligand (TRAIL), a cytokine that specifically targets cancer cells, by helping overcome TRAIL resistance. However, the therapeutic effects of curcumin are limited by its low bioavailability. Similar compounds to curcumin with higher bioavailability, such as demethoxycurcumin (DMC) and 3,5-bis(2-fluorobenzylidene)-4-piperidone (EF24), can potentially have similar anticancer effects and show a similar synergy with TRAIL, thus reducing RCC viability. This study aims to show the effects of DMC and EF24 in combination with TRAIL at reducing ACHN cell viability and ACHN cell migration. It also shows the changes in death receptor 4 (DR4) expression after treatment with these compounds individually and in combination with TRAIL, which can play a role in their mechanism of action.
- 1 December 2019
- Published by Elsevier in Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease
- Vol. 1865 (12) , 165532
Neutrophil gelatinase-associated lipocalin (NGAL) is localised to the primary cilium in renal tubular epithelial cells - A novel source of urinary biomarkers of renal injury
- 1 December 2019
- Published by Elsevier in Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease
- Vol. 1865 (12) , 165532
Neutrophil gelatinase-associated lipocalin (NGAL) is localised to the primary cilium in renal tubular epithelial cells - A novel source of urinary biomarkers of renal injury
- 1 October 2017
- Published by Elsevier in Food and Chemical Toxicology
- Vol. 108, 128-138
Reactive carbonyl compounds impair wound healing by vimentin collapse and loss of the primary cilium
- 1 October 2017
- Published by Elsevier in Food and Chemical Toxicology
- Vol. 108, 128-138
Reactive carbonyl compounds impair wound healing by vimentin collapse and loss of the primary cilium
- 1 June 2016
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 474 (3) , 579-586
Prolyl hydroxylase-1 regulates hepatocyte apoptosis in an NF-κB-dependent manner
- 1 June 2016
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 474 (3) , 579-586
Prolyl hydroxylase-1 regulates hepatocyte apoptosis in an NF-κB-dependent manner
- Open Access
- 26 April 2016
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 5 (5) , 50
Tacrolimus Modulates TGF-β Signaling to Induce Epithelial-Mesenchymal Transition in Human Renal Proximal Tubule Epithelial Cells
Epithelial-mesenchymal transition (EMT), a process which describes the trans-differentiation of epithelial cells into motile mesenchymal cells, is pivotal in stem cell behavior, development and wound healing, as well as contributing to disease processes including fibrosis and cancer progression. Maintenance immunosuppression with calcineurin inhibitors (CNIs) has become routine management for renal transplant patient, but unfortunately the nephrotoxicity of these drugs has been well documented. HK-2 cells were exposed to Tacrolimus (FK506) and EMT markers were assessed by RT PCR and western blot. FK506 effects on TGF-β mRNA were assessed by RT PCR and TGF-β secretion was measured by ELISA. The impact of increased TGF-β secretion on Smad signaling pathways was investigated. The impact of inhibition of TGF-β signaling on EMT processes was assessed by scratch-wound assay. The results presented in this study suggest that FK506 initiates EMT processes in the HK-2 cell line, with altered expression of epithelial and myofibroblast markers evident. Additionally, the study demonstrates that FK506 activation of the TGF-β/ SMAD pathways is an essential step in the EMT process. Overall the results demonstrate that EMT is heavily involved in renal fibrosis associated with CNI nephrotoxicity.
- 26 April 2016
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 5 (5) , 50
Open AccessTacrolimus Modulates TGF-β Signaling to Induce Epithelial-Mesenchymal Transition in Human Renal Proximal Tubule Epithelial Cells
Epithelial-mesenchymal transition (EMT), a process which describes the trans-differentiation of epithelial cells into motile mesenchymal cells, is pivotal in stem cell behavior, development and wound healing, as well as contributing to disease processes including fibrosis and cancer progression. Maintenance immunosuppression with calcineurin inhibitors (CNIs) has become routine management for renal transplant patient, but unfortunately the nephrotoxicity of these drugs has been well documented. HK-2 cells were exposed to Tacrolimus (FK506) and EMT markers were assessed by RT PCR and western blot. FK506 effects on TGF-β mRNA were assessed by RT PCR and TGF-β secretion was measured by ELISA. The impact of increased TGF-β secretion on Smad signaling pathways was investigated. The impact of inhibition of TGF-β signaling on EMT processes was assessed by scratch-wound assay. The results presented in this study suggest that FK506 initiates EMT processes in the HK-2 cell line, with altered expression of epithelial and myofibroblast markers evident. Additionally, the study demonstrates that FK506 activation of the TGF-β/ SMAD pathways is an essential step in the EMT process. Overall the results demonstrate that EMT is heavily involved in renal fibrosis associated with CNI nephrotoxicity.
- 18 November 2015
- Published by Wiley in The Journal of Physiology
- Vol. 593 (23) , 5167-5182
Cystine accumulation attenuates insulin release from the pancreatic β‐cell due to elevated oxidative stress and decreased ATP levels
The pancreatic β-cell has reduced antioxidant defences making it more susceptible to oxidative stress. In cystinosis, a lysosomal storage disorder, an altered redox state may contribute to cellular dysfunction. This rare disease is caused by an abnormal lysosomal cystine transporter, cystinosin, which causes excessive accumulation of cystine in the lysosome. Cystinosis associated kidney damage and dysfunction leads to the Fanconi syndrome and ultimately end-stage renal disease. Following kidney transplant, cystine accumulation in other organs including the pancreas leads to multi-organ dysfunction. In this study, a Ctns gene knockdown model of cystinosis was developed in the BRIN-BD11 rat clonal pancreatic β-cell line using Ctns-targeting siRNA. Additionally there was reduced cystinosin expression, while cell cystine levels were similarly elevated to the cystinotic state. Decreased levels of chronic (24 h) and acute (20 min) nutrient-stimulated insulin secretion were observed. This decrease may be due to depressed ATP generation particularly from glycolysis. Increased ATP production and the ATP/ADP ratio are essential for insulin secretion. Oxidised glutathione levels were augmented, resulting in a lower [glutathione/oxidised glutathione] redox potential. Additionally, the mitochondrial membrane potential was reduced, apoptosis levels were elevated, as were markers of oxidative stress, including reactive oxygen species, superoxide and hydrogen peroxide. Furthermore, the basal and activated phosphorylated forms of the redox-sensitive transcription factor NF-κB were increased in cells with silenced Ctns. From this study, the cystinotic-like pancreatic β-cell model demonstrated that the altered oxidative status of the cell, resulted in depressed mitochondrial function and pathways of ATP production, causing reduced nutrient-stimulated insulin secretion.
- 18 November 2015
- Published by Wiley in The Journal of Physiology
- Vol. 593 (23) , 5167-5182
Cystine accumulation attenuates insulin release from the pancreatic β‐cell due to elevated oxidative stress and decreased ATP levels
The pancreatic β-cell has reduced antioxidant defences making it more susceptible to oxidative stress. In cystinosis, a lysosomal storage disorder, an altered redox state may contribute to cellular dysfunction. This rare disease is caused by an abnormal lysosomal cystine transporter, cystinosin, which causes excessive accumulation of cystine in the lysosome. Cystinosis associated kidney damage and dysfunction leads to the Fanconi syndrome and ultimately end-stage renal disease. Following kidney transplant, cystine accumulation in other organs including the pancreas leads to multi-organ dysfunction. In this study, a Ctns gene knockdown model of cystinosis was developed in the BRIN-BD11 rat clonal pancreatic β-cell line using Ctns-targeting siRNA. Additionally there was reduced cystinosin expression, while cell cystine levels were similarly elevated to the cystinotic state. Decreased levels of chronic (24 h) and acute (20 min) nutrient-stimulated insulin secretion were observed. This decrease may be due to depressed ATP generation particularly from glycolysis. Increased ATP production and the ATP/ADP ratio are essential for insulin secretion. Oxidised glutathione levels were augmented, resulting in a lower [glutathione/oxidised glutathione] redox potential. Additionally, the mitochondrial membrane potential was reduced, apoptosis levels were elevated, as were markers of oxidative stress, including reactive oxygen species, superoxide and hydrogen peroxide. Furthermore, the basal and activated phosphorylated forms of the redox-sensitive transcription factor NF-κB were increased in cells with silenced Ctns. From this study, the cystinotic-like pancreatic β-cell model demonstrated that the altered oxidative status of the cell, resulted in depressed mitochondrial function and pathways of ATP production, causing reduced nutrient-stimulated insulin secretion.